Thus, these findings indicate that NELF-A phosphorylation status in vivo is tightly regulated by a balance between ERK and PP2A activities, and that PP2A can overwhelm ERK to settle NELF-A in an unphosphorylated form in these cancer cells even though basal ERK activity is elevated by various oncogenes. The gene discussed is NELFA; the disease is cancer.